Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
暂无分享,去创建一个
J. Blay | M. van Glabbeke | J. Verweij | A. Le Cesne | M. Schlemmer | P. Casali | J. Zalcberg | I. Judson | P. Reichardt | Michelle Brown | M. V. Van Glabbeke